Edgewise Therapeutics Inc

1
NAS:EWTX (USA)  
$ 16.48 +0.54 (+3.39%) 01:36 PM EST
At Loss
P/B:
3.64
Volume:
365.57K
Avg Vol (2M):
719.42K
Volume:
365.57K
At Loss
Avg Vol (2M):
719.42K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for EWTX ( Edgewise Therapeutics Inc ) from 2021 to Apr 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Edgewise Therapeutics stock (EWTX) PE ratio as of Apr 26 2024 is 0. More Details

Edgewise Therapeutics Inc (EWTX) PE Ratio (TTM) Chart

To

Edgewise Therapeutics Inc (EWTX) PE Ratio (TTM) Historical Data

Total 777
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 9
Edgewise Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-04-01 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss

Edgewise Therapeutics Inc (EWTX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Edgewise Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US28036F1057
Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.